Glycoprotein IIb/IIIa inhibition attenuates platelet-activating factor-induced platelet activation by reducing protein kinase C activity

Journal of Thrombosis and Haemostasis

Volumn 1, Issue 8, 2003, Pages 1805-1812

  Hu, H ^a   Zhang, W ^b   Li, N ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Gpiib IIIa inhibitor; Platelet activating factor; Platelets; Protein kinase C

Indexed keywords

ADENOSINE DIPHOSPHATE; CD11B ANTIGEN; FIBRINOGEN RECEPTOR; MAP2K1 PROTEIN, HUMAN; MAP2K2 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; MONOCLONAL ANTIBODY; PADGEM PROTEIN; PEPTIDE; PEPTIDE FRAGMENT; PROTEIN KINASE C; PROTEIN TYROSINE KINASE; THROMBIN RECEPTOR PEPTIDE SFLLRNP; THROMBOCYTE ACTIVATING FACTOR; THROMBOXANE A2 RECEPTOR;

ADOLESCENT; ADULT; ARTICLE; BIOSYNTHESIS; CHEMISTRY; DOSE RESPONSE; DRUG ANTAGONISM; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOBLOTTING; LEUKOCYTE; MALE; METABOLISM; MIDDLE AGED; PHOSPHORYLATION; THROMBOCYTE; THROMBOCYTE ACTIVATION; TIME;

ADENOSINE DIPHOSPHATE; ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD11B; BLOOD PLATELETS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOBLOTTING; LEUKOCYTES; MALE; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MITOGEN-ACTIVATED PROTEIN KINASES; P-SELECTIN; PEPTIDE FRAGMENTS; PEPTIDES; PHOSPHORYLATION; PLATELET ACTIVATING FACTOR; PLATELET ACTIVATION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROTEIN KINASE C; PROTEIN-TYROSINE KINASES; RECEPTORS, THROMBOXANE A2, PROSTAGLANDIN H2; TIME FACTORS;

EID: 2142758598     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1046/j.1538-7836.2003.00324.x     Document Type: Article

References (35)

1. Quinn MJ, Plow EF, Topol EJ. Platelet glycoprotein Ilb/IIIa inhibitors: recognition of a two-edged sword? Circulation 2002; 106: 379-85.
2. Reverter JC, Beguin S, Kessels H, Kumar R, Hemker HC, Coller BS. Inhibition of platelet-mediated, tissue factor-induced thrombin genera tion by the mouse/human chimeric 7E3 antibody. J Clin Invest 1996; 98: 863-74.
3. Furman MI, Krueger LA, Frelinger AL, Barnard MR, Mascelli MA, Nakada MT, Michelson AD. GPIIb-IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatidylserine expression in whole blood. Thromb Haemost 2000; 84: 492-8.
4. Gemmell CH, Sefton MV, Yeo EL. Platelet-derived microparticle formation involves glycoprotein Ilb-IIIa. Inhibition by RGDS and a Glanzmann's thrombasthenia defect. J Biol Chem 1993; 268: 14586-9.
5. Gibson CM, de Lemos JA, Murphy SA, Marble SJ, McCabe CH, Cannon CP, Antman EM, Braunwald E. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: aTIMI 14 substudy. Circulation 2001; 103: 2550-4.
6. Palmerini T, Nedelman MA, Scudder LE, Nakada MT, Jordan RE, Smyth S, Gordon RE, Fallon JT, Coller BS. Effects of abciximab on the acute pathology of blood vessels after arterial stenting in nonhuman primates. J Am Coll Cardiol 2002; 40: 360-6.
7. Mousa SA, Khurana S, Forsythe MS. Comparative in vitro efficacy of different platelet glycoprotein Ilb/IIIa antagonists on platelet-mediated clot strength induced by tissue factor with use of thromboelastography: differentiation among glycoprotein Ilb/IIIa antagonists. Arterioscler Thromb Vase Biol 2000; 20: 1162-7.
8. Collet JP, Montalescot G, Lesty C, Weisel JW. A structural and dynamic investigation of the facilitating effect of glycoprotein Ilb/IIIa inhibitors in dissolving platelet-rich clots. Circ Res 2002; 90: 428-34.
9. Kupatt C, Habazettl H, Hanusch P, Wichels R, Hahnel D, Becker BF, Boekstegers P. c7E3 Fab reduces postischemic leukocyte-thrombocyte interaction mediated by fibrinogen: implications for myocardial reper-fusion injury. Arterioscler Thromb Vase Biol 2000; 20: 2226-32.
10. Aymong ED, Curtis MJ, Youssef M, Graham MM, Shewchuk L, Leschuk W, Anderson TJ. Abciximab attenuates coronary microvas-cular endothelial dysfunction after coronary stenting. Circulation 2002; 105: 2981-5.
11. Lincoff AM, Kereiakes DJ, Mascelli MA, Deckelbaum LI, Barnathan ES, Patel KK, Frederick B, Nakada MT, Topol EJ. Abciximab sup presses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation 2001; 104: 163-7.
12. 3: inside-out, outside-in, and sideways. Thromb Haemost 1999; 82: 318-25.
13. 3 in platelets. J Biol Chem 1997; 272: 22381-4.
14. Bugaud F, Nadal-Wollbold F, Levy-Toledano S, Rosa JP, Bryckaert M. Regulation of c-jun-NH2 terminal kinase and extracellular-signal regu lated kinase in human platelets. Blood 1999; 94: 3800-5.
15. Li N, Hu H, Lindqvist M, Wikstrom-Jonsson E, Goodall AH, Hjemdahl P. Platelet-leukocyte cross talk in whole blood. Arterioscl Thromb Vase Biol 2000; 20: 2702-8.
16. Li N, Goodall AH, Hjemdahl P. A sensitive flow cytometric assay for circulating platelet-leucocyte aggregates. Br J Haematol 1997; 99: 808-16.
17. do Ceu Monteiro M, Sansonetty F, Goncalves MJ, O'Connor JE. Flow cytometric kinetic assay of calcium mobilization in whole blood platelets using Fluo-3 and CD41. Cytometry 1999; 35: 302-10.
18. Li N, Halldén G, Hjemdahl P. A whole-blood flow cytometric assay for leukocyte CDllb expression using fluorescence signal triggering. Eur J Haematol 2000; 65: 57-65.
19. Li N, Goodall AH, Hjemdahl P. Efficient flow cytometric assay for platelet-leukocyte aggregates in whole blood using fluorescence signal triggering. Cytometry 1999; 35: 154-61.
20. 2+ entry via btk in platelets and megakaryocytes without increasing phospholipase C activity. EMBO J 2000; 19: 2793-802.
21. Tselepis AD, Goudevenos JA, Tambaki AP, Michalis L, Stroumbis CS, Tsoukatos DC, Elisaf M, Sideris DA. Platelet aggregatory response to platelet activating factor (PAF), ex vivo, and PAF-acetylhydrolase activity in patients with unstable angina: effect of c7E3 Fab (abciximab) therapy. Cardiovasc Res 1999; 43: 183-91.
22. Peters RJG, Moons AHM. Platelet function and coronary artery disease. Eur J Clin Invest 2001; 31: 3-5.
23. Lindemann S, Tolley ND, Dixon DA, Mclntyre TM, Prescott SM, Zimmerman GA, Weyrich AS. Activated platelets mediate inflammatory signaling by regulated interleukin 1β synthesis. J Cell Biol 2001; 154: 485-90.
24. 3) on platelets upregulates CD40L and triggers CD40L-dependent matrix degradation by endothe lial cells. Circulation 2002; 106: 2111-7.
25. Taylor ML, Misso NL, Stewart GA, Thompson PJ. The effects of varying doses of aspirin on human platelet activation induced by PAF, collagen and arachidonic acid. Br J Clin Pharmacol 1992; 33: 25-31.
26. Packham MA, Kinlough-Rathbone RL, Mustard JF. Thromboxane A2 causes feedback amplification involving extensive thromboxane A2 formation on close contact of human platelets in media with a low concentration of ionized calcium. Blood 1987; 70: 647-51.
27. 2+ influx into stimulated platelets. Blood 1985; 66: 731-4.
28. 3 modulates store-mediated calcium entry in human platelets. Blood 2001; 97: 2648-56.
29. 2+ signaling. Blood 1998; 92: 3675-83.
30. 2 synthesis. Thromb Haemost 1998; 79: 1184-90.
31. Ware JA, Decenzo MT, Smith M, Saitoh M. Calcium mobilization and glycoprotein IIb-IIIa complex ligands in epinephrine-stimulated plate lets. Am J Physiol 1991; 260: H1619-24.
32. 3) and the platelet-activating factor: dissociation between adhesion and aggregation. Blood 2002; 99: 2819-27.
33. Samiei M, Sanghera JS, Pelech SL. Activation of myelin basic protein and S6 peptide kinases in phorbol ester- and PAF-treated sheep platelets. Biochim Biophys Acta 1993; 1176: 287-98.
34. Xiao Z, Theroux P, Frojmovic M. Modulation of platelet-neutrophil interaction with pharmacological inhibition of fibrinogen binding to platelet GPIIb/IIIa receptor. Thromb Haemost 1999; 81: 281-5.
35. Mickelson JK, Ali MN, Kleiman NS, Lakkis NM, Chow TW, Hughes BJ, Smith CW Chimeric 7E3 Fab (ReoPro) decreases detectable CD1 lb on neutrophils from patients undergoing coronary angioplasty. J Am Coll Cardiol 1999; 33: 97-106.